摘要
目的探讨血清中miR-375作为在肝细胞癌(HCC)预后评估生物标志的可能。方法采用qRT-PCR的方法 ,检测2011至2012年间接受过肿瘤切除术的65例被确诊为HCC的患者血清中miR-375的表达水平,并经随访统计各位患者生存期情况。用X^2检验来比较miR-375的表达差异,用Kaplan Meier分析其生存状态,用多因素Cox回归分析预后情况。结果 40例(61.5%)HCC患者血清中miR-375的表达较高,其余25例(38.5%)表达则较低,且其在高分化、Ⅲ或Ⅳ期的患者中均显著增高。miR-375高表达患者的总生存期及无病生存期长于较低表达的患者。结论 miR-375可能与HCC的发生、发展及预后有关,或可作判断HCC预后及治疗的一个新的生物标志物。
Objective To investigate the potential of the serum miR- 375 as a biomarker in the prognosis of hepatocellular carcinoma (HCC). Methods The qRT- PCR was used to detect the expression of miR- 375 in the serum of 65 patients with HCC who had undergone tumor resection between 2011 and 2012.The survival periods of the patients were also followed up.Differences in the expression of miR- 375 were compared using the χ^2 test.Kaplan Meier method was performed to analyze the survival status and the multivariate Cox regression was used for prognostic analysis. Results There are 40 (61.5%)HCC patients whose expression levels of serum miR- 375 were relatively higher,while the other 25 (38.5%)cases were lower,and they were significantly increased in patients with well- differentiated,stage III or IV tumors.Compared with patients with low expression of miR- 375,patients with high expression of miR- 375 had a longer disease- free survival and overall survival.Through the Cox multivariate analysis,the expression level of miR- 375,the degree of cancer differentiation,and staging were all related to disease- free survival and overall survival. Conclusion MiR- 375 might be related to the occurrence,development and prognosis of HCC,or it could be a novel biomarker to facilitate the prognosis and treatment of HCC.
作者
安阳
赵文超
夏念信
朱林忠
邱宝安
AN Yang;ZHAO Wen-chao;XIA Nian-xin;ZHU Lin-zhong;QIU Bao-an(Department of Hepatobiliary Surgery,Navy General Hospital,Beijing 100048,China;Department ofInterventional Therapy, Cancer Hospital of Peking University and Beijing Institute of Cancer Prevention andTreatment,Research Laboratory of Cancer Pathogenesis and Transformation,Beijing 100048,China)
出处
《标记免疫分析与临床》
CAS
2019年第1期10-12,27,共4页
Labeled Immunoassays and Clinical Medicine
基金
国家重点研发计划(编号:2016YFC0106604)
国家自然科学基金(编号:81502591)
